Orbits Oncology
- Company typePrivate
- Founded2019
- HeadquartersSan Francisco, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
Orbits Oncology firmographics
Firmographics- Name
- Orbits Oncology
- Legal name
- Orbits Oncology
- Website
- https://orbits-oncology.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Orbits Oncology industry classification
Industry- Product category
- AI Image Analysis Software for Organoid Drug Screening
- NAICS
- Software Publishers (5132)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industry
- In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)
Keywords
Where Orbits Oncology is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Orbits Oncology business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations
Revenue model
- Software Platform Subscription: Cloud-based AI image analysis platform accessible via app.orbits-oncology.com. Customers access the platform for analyzing imaging data from their in-vitro models. Pricing is quote-based, suggesting enterprise-level subscription contracts.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise pricing for pharmaceutical and research institutions |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Orbits Oncology product offering
Product offeringCore offering
Orbits Oncology develops and sells an AI-powered computational platform that converts live-cell imaging data from complex 3D in-vitro models (organoids, spheroids, co-cultures, microtissues) into quantitative, scalable phenotypic intelligence. The cloud-based platform delivers end-to-end workflows covering image upload, plate-layout management, segmentation, morphology classification, dynamic readouts, and export of analysis-ready results, and is sold via enterprise annual subscriptions to pharmaceutical companies and research institutions.
Product overview
Orbits Oncology offers a single unified AI-powered platform called the Orbits Platform. This platform provides a standardized workflow for analyzing complex in-vitro models through image capture, upload, segmentation, classification, and quantification of phenotypic responses. The platform supports applications in cancer/tumoroid drug screening (with metrics like NOGR, IC50, AUC), toxicology screening, cardiac contractility measurement, and neural model analysis. It integrates with major live-cell imaging systems (Tecan, Sartorius, Agilent, Molecular Devices, ZEISS, Revvity) and supports both brightfield and fluorescence modalities.
Differentiator
Problem solved
Functional benefit
Products and services
- Orbits Platform
Quantifiable outcome
- Automated detection of organoids and cell death areas without manual annotation
- +2 more outcomes
Companies that use Orbits Oncology
Customer profileSegments4 records
Ideal customer profiles2 records
Orbits Oncology technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration6 records
AI capability3 records
Feature6 records
Orbits Oncology partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Thermo Fisher ScientificcoreJoint webinar partnership with Thermo Fisher Scientific on 'Advancing cancer organoid drug screening with novel media systems'. Colin Paul (Thermo Fisher) introduced OncoPro medium while Christophe Deben (Orbits) demonstrated imaging software capabilities for high-content analysis.
Scale indicators3 records
Recent moves7 records
Expansion highlights4 records
Orbits Oncology competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Orbits Oncology social profiles
Digital presenceOrbits Oncology financial estimates
Financial estimateRevenue estimate
Valuation estimate
Orbits Oncology leadership team
Management profileNumber of profiles
Profiles6 records
Orbits Oncology funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Orbits Oncology M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Orbits Oncology
What does Orbits Oncology do?
Orbits Oncology develops and sells an AI-powered computational platform that converts live-cell imaging data from complex 3D in-vitro models (organoids, spheroids, co-cultures, microtissues) into quantitative, scalable phenotypic intelligence. The cloud-based platform delivers end-to-end workflows covering image upload, plate-layout management, segmentation, morphology classification, dynamic readouts, and export of analysis-ready results, and is sold via enterprise annual subscriptions to pharmaceutical companies and research institutions.
Is Orbits Oncology a public or private company?
Orbits Oncology is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Orbits Oncology founded?
Orbits Oncology was founded in 2019. It employs 1 to 10 people.
Where is Orbits Oncology based?
Orbits Oncology is headquartered in San Francisco, United States, in the North America region.
How does Orbits Oncology make money?
One revenue line is on record: software Platform Subscription.
Does Orbits Oncology have an API?
No public API is recorded for Orbits Oncology.
What industry is Orbits Oncology in?
Orbits Oncology's product category is AI Image Analysis Software for Organoid Drug Screening. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems). Its NAICS code is 5132 and its SIC code is 7372.